#RSNA 14: Screening Dense Breasts: Connecticut Experience
The researchers collected data from two practices with five sites in Connecticut. In years 3 and 4 of the study the results were:
Year 3: 32,230 screening mammograms, 4128 screening ultrasounds. Of these 3819 cases were BIRADS 1 or 2, 168 were BIRADS 3, and 148 were BIRADS 4 or 5, of which 13 had a positive biopsy.
Year 4: 27,937 screening mammograms, 3331 screening ultrasounds, 2889 BIRADs 1 or 2, 358 BIRADS 3, 53 BIRADS 4 or 5 of which 11 had a positive biopsy.
For year 3 the positive predictive value was 8.1%, cancers per thousand were 3.2 and the percentage of eligible women having the study was 32%. For year 4, the positive predictive value was 14.2%, there were 3.3 cancers per thousand, and 28% of eligible women were having the study. Weigert observed that by year 4 they were no longer performing biopsies for things that did not need to be biopsied. Around 30% of women eligible for adjunct screening come for testing. Weigert suggested that this may be due to lack of awareness, but more likely is due to cost and insurance issues.
Concluded Weigert, screening breast ultrasound in women with mammographically dense breast tissue (more than 50% of the screening population) does find occult cancers. Their research has shown that this has continued at the same rate per thousand over the first four years since the breast density inform legislation was enacted in Connecticut. The positive predictive value has improved, demonstrating that there is a learning curve in deciding which lesions to follow and which to biopsy. Cancers are found in women having yearly ultrasonography. Higher grade tumours are the lesions more likely to have positive sentinel nodes. There is no association of risk factors other than dense breasts in this group of patients. There has been a progressive decrease in the size of lesions detected with the largest lesions in Year 1, and average size is currently less than 1cm. Women having repeat ultrasound are now having cancers diagnosed indicating that in this patient population this test should be part of their routine yearly screening procedure.
Managing Editor, HealthManagement
Image source: Wikimedia Commons
Published on : Fri, 5 Dec 2014
Better detection. Clinically superior. Low dose.** What if we could find breast cancers earlier? See lesions more clearly? Reduce the number of unnecessary biopsies? Questions like these inspired Hologic researchers and scientists to develop Hologic...
THE VEVO MD IS THE WORLD’S FIRST ULTRA HIGH FREQUENCY ULTRASOUND SYSTEM DESIGNED FOR CLINICAL USE WITH FREQUENCIES UP TO 70 MHz. This groundbreaking technology opens up new possibilities for medical imaging that have never been seen before. Whether...
We recognize that the best chance any patient has at getting better is a clinician at their bedside with all the right answers and the confidence to act. SonoSite education and training is the industry standard – no other point-of-care ultrasound manufacturer...
Sonosite's Most Advanced Image Clarity, Ever Inspired and designed by working side-by-side with clinicians, Sonosite PX offers our most advanced image clarity for an unparalleled level of confidence when treating and diagnosing patients. The new interface...